Scientific article
Open access

Lung cancer mortality risk among breast cancer patients treated with anti-estrogens

Published inCancer, vol. 117, no. 6, p. 1288-1295
Publication date2011

The Women's Health Initiative randomized clinical trial reported that menopausal hormone therapy increases lung cancer mortality risk. If this is true, use of anti-estrogens should be associated with decreased lung cancer mortality risk. The authors compared lung cancer incidence and mortality among breast cancer patients with and without anti-estrogen therapy.

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents/therapeutic use
  • Breast Neoplasms/complications/drug therapy/mortality
  • Carcinoma/complications/drug therapy/mortality
  • Cohort Studies
  • Estrogen Receptor Modulators/therapeutic use
  • Female
  • Humans
  • Incidence
  • Lung Neoplasms/complications/drug therapy/etiology/mortality
  • Middle Aged
  • Registries
  • Risk Factors
Citation (ISO format)
BOUCHARDY MAGNIN, Christine et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. In: Cancer, 2011, vol. 117, n° 6, p. 1288–1295. doi: 10.1002/cncr.25638
Main files (1)
Article (Published version)
ISSN of the journal0008-543X

Technical informations

Creation11/20/2012 2:17:00 PM
First validation11/20/2012 2:17:00 PM
Update time03/14/2023 5:46:46 PM
Status update03/14/2023 5:46:46 PM
Last indexation08/29/2023 5:20:24 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack